Sentry BioPharma Services Offers Clinical Trial Support for Muscular Dystrophy
July 25, 2016
Sentry BioPharma Services serves pharmaceutical and biotechnology firms developing drugs for multiphase clinical trials for various indications. One such indication is muscular dystrophy (MD). According to the Muscular Dystrophy Association’s (MDA’s) website, “Muscular dystrophy, amyotrophic lateral sclerosis (ALS) and related muscle-debilitating diseases take away a person’s physical strength, independence and life.”
Source: https://www.cdc.gov/ncbddd/musculardystrophy/freematerials.html
The National Institute of Neurological Disorders and Stroke (NINDS) indicates there is no specific prescription drug, biological product or vaccine to prevent, stop or reverse any form of MD. Treatment may include physical therapy, respiratory therapy, speech therapy, orthopedic appliances used for support, and corrective orthopedic surgery. Drug therapy includes corticosteroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, immunosuppressants to delay some damage to dying muscle cells, and antibiotics to fight respiratory infections. Some individuals may benefit from occupational therapy and assistive technology. Some patients may need assisted ventilation to treat respiratory muscle weakness and a pacemaker for cardiac abnormalities.
Some of the life-threatening diseases are as follows:
- Acid Maltase Deficiency (AMD)
- Amyotrophic Lateral Sclerosis (ALS)
- Andersen-Tawil Syndrome
- Becker Muscular Dystrophy (BMD)
- Becker Myotonia Congenita
- Bethlem Myopathy
- Bulbospinal Muscular Atrophy (Spinal-Bulbar Muscular Atrophy)
- Carnitine Deficiency
- Carnitine Palmityl Transferase Deficiency (CPT Deficiency)
- Central Core Disease (CCD)
- Centronuclear Myopathy
- Charcot-Marie-Tooth Disease (CMT)
- Congenital Muscular Dystrophy (CMD)
- Congenital Myasthenic Syndromes (CMS)
- Congenital Myotonic Dystrophy
- Cori Disease (Debrancher Enzyme Deficiency)
- Debrancher Enzyme Deficiency
- Dejerine-Sottas Disease (DSD)
- Dermatomyositis (DM)
- Distal Muscular Dystrophy (DD)
- Duchenne Muscular Dystrophy (DMD)
- Dystrophia Myotonica (Myotonic Muscular Dystrophy)
- Emery-Dreifuss Muscular Dystrophy (EDMD)
- Endocrine Myopathies
- Eulenberg Disease (Paramyotonia Congenita)
- Facioscapulohumeral Muscular Dystrophy (FSH or FSHD)
- Finnish (Tibial) Distal Myopathy
- Forbes Disease (Debrancher Enzyme Deficiency)
- Friedreich’s Ataxia (FA)
- Fukuyama Congenital Muscular Dystrophy
- Glycogenosis Type 10
- Glycogenosis Type 11
- Glycogenosis Type 2
- Glycogenosis Type 3
- Glycogenosis Type 5
- Glycogenosis Type 7
- Glycogenosis Type 9
- Gowers-Laing Distal Myopathy
- Hauptmann-Thanheuser MD (Emery-Dreifuss Muscular Dystrophy)
- Hereditary Inclusion-Body Myositis
- Hereditary Motor and Sensory Neuropathy (Charcot-Marie-Tooth Disease)
- Hyperthyroid Myopathy
- Hypothyroid Myopathy
- Inclusion-Body Myositis (IBM)
- Inherited Myopathies
- Integrin-Deficient Congenital Muscular Dystrophy
- Kennedy Disease (Spinal-Bulbar Muscular Atrophy)
- Kugelberg-Welander Disease (Spinal Muscular Atrophy)
- Lactate Dehydrogenase Deficiency
- Lambert-Eaton Myasthenic Syndrome (LEMS)
- Limb-Girdle Muscular Dystrophy (LGMD)
- Lou Gehrig’s Disease (Amyotrophic Lateral Sclerosis)
- McArdle Disease (Phosphorylase Deficiency)
- Merosin-Deficient Congenital Muscular Dystrophy
- Metabolic Diseases of Muscle
- Mitochondrial Myopathy
- Miyoshi Distal Myopathy
- Motor Neurone Disease
- Muscle-Eye-Brain Disease
- Myasthenia Gravis (MG)
- Myoadenylate Deaminase Deficiency
- Myofibrillar Myopathy
- Myophosphorylase Deficiency
- Myotonia Congenita (MC)
- Myotonic Muscular Dystrophy (MMD)
- Myotubular Myopathy (MTM or MM)
- Nemaline Myopathy
- Nonaka Distal Myopathy
- Oculopharyngeal Muscular Dystrophy (OPMD)
- Paramyotonia Congenita
- Pearson Syndrome
- Periodic Paralysis
- Peroneal Muscular Atrophy (Charcot-Marie-Tooth Disease)
- Phosphofructokinase Deficiency
- Phosphoglycerate Kinase Deficiency
- Phosphoglycerate Mutase Deficiency
- Phosphorylase Deficiency
- Polymyositis (PM)
- Pompe Disease (Acid Maltase Deficiency)
- Progressive External Ophthalmoplegia (PEO)
- Rod Body Disease (Nemaline Myopathy)
- Spinal Muscular Atrophy (SMA)
- Spinal-Bulbar Muscular Atrophy (SBMA)
- Steinert Disease (Myotonic Muscular Dystrophy)
- Tarui Disease (Phosphofructokinase Deficiency)
- Thomsen Disease (Myotonia Congenita)
- Ullrich Congenital Muscular Dystrophy
- Walker-Warburg Syndrome (Congenital Muscular Dystrophy)
- Welander Distal Myopathy
- Werdnig-Hoffmann Disease (Spinal Muscular Atrophy)
- ZASP-Related Myopathy
According to ClinicalTrial.gov, an on-line service provided to the public by the U.S. National Institutes of Health (NIH), there are approximately 125 open clinical studies in process currently.
Strict adherence to clinical trial material management protocols, in combination with proven GMP storage, clinical trial labeling, secondary packaging and global drug distribution allows Sentry to provide clinical trial outsourcing clients with a variety of flexible services.
For more information about how Sentry BioPharma Services can integrate your requirements into a scalable, secure, value-added clinical trial logistics solution, contact Sentry via email or by phone at 1-866-757-7400.